Wrexham have taken a significant step toward boosting their stadium’s capacity, having officially submitted a planning application to Wrexham City Borough Council. The club aims to add an extra 2,250 ...

Matty James says he has been grateful for his "crazy" spell at Wrexham so far following a "whirlwind" summer last year. The ...

The market expects Stoke Therapeutics, Inc. (STOK) to deliver a year-over-year decline in earnings on higher revenues when it ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Wrexham ’s Racecourse Ground will have a new name next season for the second time in its history following a lucrative sponsorship deal that is expected to earn the club a substantial seven ...

STOK Company Profile Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Wrexham's Racecourse Ground will be renamed the SToK Racecourse for next season in a deal that sees the world's oldest international stadium have a title sponsor for the first time. The stadium ...

STOK has a tiny market cap of $629.50 million and a rather large “short interest” of more than 21%. Last quarter the company saw a nice beat on both earnings ($1.90) and revenues ($158 million ...

The latest price target for Stoke Therapeutics (NASDAQ:STOK) was reported by Jefferies on July 18, 2025. The analyst firm set a price target for $30.00 expecting STOK to rise to within 12 months ...